In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:

• Key Comorbidities in Patients with HR+/HER2- MBC
• Impact of Polypharmacy
• Role of APPs in Comprehensive Care
• Role of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBC
• Utility of RWE data
• Communicating Treatment Options With Patients and Caregivers
• Understanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of Life

Link to full program:
https://bit.ly/4jCQe38

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers.

• Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, neuropathy, and cytopenia across ADCs
• On-Target vs Off-Target Effects: How linker design, payload type, and drug-to-antibody ratio (DAR) contribute to toxicity
• Combination Therapy Considerations: Challenges in combining ADCs with immunotherapy or chemotherapy due to overlapping toxicities and tolerability concerns
   

Presenters:

Catherine Fahey, MD, PhD
Assistant Professor
Division of Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Alexandra Leary, MD, PhD
President, GINECO Group
Co-Director, Department of Medical Oncology
Medical Oncologist Gynecology
Team Leader, Gynecologic Translational Research Lab, INSERM u981
Institut Gustave Roussy
Villejuif, France

Funda Meric-Bernstam, MD
Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
The University of Texas MD Anderson Cancer Center
Houston, Texas

Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director of GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Link to full program: 
https://bit.ly/42iEDjV

To claim credit for listening to this episode, please visit the podcast online at the link above. 

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers.

• Mechanisms of action of ADCs: how ADCs selectively deliver potent chemotherapy to tumor cells
• Clinical data across tumor types: highlights from recent trials with trastuzumab deruxtecan and exploration of emerging data on agents such as disitamab vedotin
• Challenges and future directions:key considerations for combining HER2-targeted ADCs with immunotherapy or chemotherapy, and sequencing ADC therapies

Presenters:

Catherine Fahey, MD, PhD
Assistant Professor
Division of Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Alexandra Leary, MD, PhD
President, GINECO Group
Co-Director, Department of Medical Oncology
Medical Oncologist Gynecology
Team Leader, Gynecologic Translational Research Lab, INSERM u981
Institut Gustave Roussy
Villejuif, France

Funda Meric-Bernstam, MD
Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
The University of Texas MD Anderson Cancer Center
Houston, Texas

Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director of GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Link to full program:
https://bit.ly/42iEDjV

To claim credit for listening to this episode, please visit the podcast online at the link above. 

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:

• Common comorbidities and complexities in managing patients with HR+/HER2- MBC
• Treatment landscape for patients with HR+/HER2- MBC
• Real-world studies in women with HR+/HER2- MBC
• Mitigation and management of drug interactions and multidisciplinary team coordination treatment selection
• Patient goals and coordinating with multidisciplinary team to maximize quality of life

Link to full program:
https://bit.ly/4jCQe38

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: 

• Rationale for targeting B7-H3
• Overview of the structure of antibody-drug conjugates (ADCs)
• Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLC
• Data from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLC
• An overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLC
• Early phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093

Program faculty:

Lauren Byers, MD
Professor and Thoracic Section Chief
Department of Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
Houston, Texas

Christine L. Hann, MD, PhD
Associate Professor of Oncology
Director, Small Cell Lung Cancer Therapeutics
Johns Hopkins University School of Medicine
Baltimore, Maryland

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. 

• HER2 Testing in Advanced Cancers: Recommendations for when and how to test for HER2 in advanced cancers and how these tests guide therapy selection
• Variability in HER2 Expression Across Tumor Types: Insights into the heterogeneity of HER2 expression and amplification in different cancers
• Challenges in Standardizing HER2 Testing: The complexities of scoring and testing HER2 in different cancers and institutions, and the need for better harmonization of guidelines and approaches

Presenters:
Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director of GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Funda Meric-Bernstam, MD
Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
The University of Texas MD Anderson Cancer Center
Houston, Texas

Alexandra Leary, MD, PhD
President, GINECO Group
Co-Director, Department of Medical Oncology
Medical Oncologist Gynecology
Team Leader, Gynecologic Translational Research Lab, INSERM u981
Institut Gustave Roussy
Villejuif, France

Catherine Fahey, MD, PhD
Assistant Professor
Division of Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Link to full program:
https://bit.ly/42iEDjV

To claim credit for listening to this episode, please visit the podcast online at the link above. 

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including:

• Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive metastatic breast cancer and 2 or fewer previous therapies
• Treatment sequencing and preferred treatment options in patients with brain metastases
• Results from phase III PATINA trial of trastuzumab, pertuzumab, plus endocrine therapy with or without palbociclib in hormone-receptor positive/HER2-positive metastatic breast cancer
• Thoughts on the use of T-DXd earlier in the treatment paradigm in light of recent results from the PATINA trial and highly anticipated results from the DESTINY-Breast09 trial

Program faculty:

Stephanie L. Graff, MD, FACP, FASCO
Director of Breast Oncology, Brown University Health
Co-Lead, Breast Cancer Translational Disease Research Group
Legorreta Cancer Center at Brown University
Associate Professor of Medicine
Warren Alpert Medical School of Brown University
Providence, Rhode Island

Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts 

Resources:
To access the patient cases associated with this podcast discussion, please visit the program page and register for an upcoming webinar on this topic.

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical pearls include:

• Adjuvant treatment selection recommendations for patients with HR-positive/HER2-negative early breast cancer based on disease and patient characteristics as well as the latest data and guidelines presented by Dr. Gradishar
• Therapeutic strategies for patients diagnosed with HR-positive/HER2-negative metastatic breast cancer (MBC) presented by Dr. Abraham
• Addressing challenges related to CDK4/6 inhibitor adherence and adverse event mitigation presented by Dr. Spring

Presenters:

Jame Abraham, MD, FACP
Enterprise Chair and Professor of Medicine
Department of Hematology and Medical Oncology
Cleveland Clinic
Cleveland, Ohio

William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Laura Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Link to full program including downloadable slides and on-demand webcasts: 
https://bit.ly/4b5GFqq

To claim credit for listening to this episode, please visit the podcast online at the link above.

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:

• Early results with teclistamab combined with anti-CD38 therapy
• Real-world data with teclistamab including its use after other BCMA-targeted therapies
• Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
• Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy

Presenter:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematologic Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, Minnesota

Link to full program:
https://bit.ly/40bjFCZ

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:

• Estrogen receptor mutations in patients With HR-positive/HER2-negative advanced breast cancer
• Current guideline recommendations for when to pursue ESR1 mutation testing mutations in patients with HR-positive/HER2-negative advanced breast cancer
• Choice and sequencing of next line of systemic therapy for ESR1-mutated advanced breast cancer based on tumor molecular alterations
• Overview of class-related and unique adverse events with approved and emerging oral SERDS
• Expert recommendations for the management of oral SERDs-related adverse events

Program faculty:

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology 
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Erica L. Mayer, MD, MPH
Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts 

Resources:
To download the slides associated with this podcast discussion, please visit the program page.